Vitamin D, cardiovascular disease, and survival in dialysis patients

Journal of Bone and Mineral Research

Volumn 22, Issue SUPPL. 2, 2007, Pages

  Moe, Sharon M ^a,b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b RICHARD L ROUDEBUSH VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Calcitriol; Chronic kidney disease; Dialysis; Heart; Paricalcitol; Vitamin D

Indexed keywords

ALFACALCIDOL; CALCITRIOL; DOXERCALCIFEROL; PARATHYROID HORMONE; PARICALCITOL; VITAMIN D;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR EFFECT; CONFERENCE PAPER; DISEASE ASSOCIATION; HEART LEFT VENTRICLE HYPERTROPHY; HEMODIALYSIS PATIENT; HUMAN; METHODOLOGY; MORTALITY; NONHUMAN; PATIENT SAFETY; PROSPECTIVE STUDY; SURVIVAL; TREATMENT DURATION; VALIDITY;

CALCITRIOL; CARDIOVASCULAR DISEASES; HUMANS; RENAL DIALYSIS; SURVIVAL ANALYSIS; VITAMIN D;

EID: 39749096575     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/jbmr.07s218     Document Type: Conference Paper

References (32)

1. Levin A, Bakris GL, Molitch M, Smulders M, Tian J, Williams LA, Andress DL 2007 Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: Results of the study to evaluate early kidney disease. Kidney Int 71:31-38.
2. Young EW, Albert JM, Satayathum S, Goodkin DA, Pisoni RL, Akiba T, Akizawa T, Kurokawa K, Bommer J, Piera L, Port FK 2005 Predictors and consequences of altered mineral metabolism: The Dialysis Outcomes and Practice Patterns Study. Kidney Int 67:1179-1187.
3. Souberbielle JC, Boutten A, Carlier MC, Chevenne D, Coumaros G, Lawson-Body E, Massart C, Monge M, Myara J, Parent X, Plouvier E, Houillier P 2006 Inter-method variability in PTH measurement: Implication for the care of CKD patients. Kidney Int 70:345-350.
4. K/DOQI NKF 2003 Clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 42(Suppl):S1-S201.
5. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM 2004 Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 15:2208-2218.
6. Chertow GM, Burke SK, Raggi P 2002 Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 62:245-252.
7. Couttenye MM, D'Haese PC, Deng JT, Van Hoof VO, Verpooten GA, De Broe ME 1997 High prevalence of adynamic bone disease diagnosed by biochemical markers in a wide sample of the European CAPD population. Nephrol Dial Transplant 12:2144-2150.
8. Brown AJ, Dusso AS, Slatopolsky E 2002 Vitamin D analogues for secondary hyperparathyroidism. Nephrol Dial Transplant 17(Suppl 10):10-19.
9. Sprague SM, Llach F, Amdahl M, Taccetta C, Batlle D 2003 Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int 63:1483-1490.
10. Teng M, Wolf M, Lowrie E, Ofsthun N, Lazarus JM, Thadhani R 2003 Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 349:446-456.
11. Dobrez DG, Mathes A, Amdahl M, Marx SE, Melnick JZ, Sprague SM 2004 Paricalcitol-treated patients experience improved hospitalization outcomes compared with calcitriol-treated patients in real-world clinical settings. Nephrol Dial Transplant 19:1174-1181.
12. Teng M, Wolf M, Ofsthun MN, Lazarus JM, Hernan MA, Camargo CA Jr, Thadhani R 2005 Activated injectable vitamin D and hemodialysis survival: A historical cohort study. J Am Soc Nephrol 16:1115-1125.
13. Tentori F, Hunt WC, Stidley CA, Rohrscheib MR, Bedrick EJ, Meyer KB, Johnson HK, Zager PG 2006 Mortality risk among hemodialysis patients receiving different vitamin D analogs. Kidney Int 70:1858-1865.
14. Kalantar-Zadeh K, Kuwae N, Regidor DL, Kovesdy CP, Kilpatrick RD, Shinaberger CS, McAllister CJ, Budoff MJ, Salusky IB, Kopple JD 2006 Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int 70:771-780.
15. Melamed ML, Eustace JA, Plantinga L, Jaar BG, Fink NE, Coresh J, Klag MJ, Powe NR 2006 Changes in serum calcium, phosphate, and PTH and the risk of death in incident dialysis patients: A longitudinal study. Kidney Int 70:351-357.
16. Shoji T, Shinohara K, Kimoto E, Emoto M, Tahara H, Koyama H, Inaba M, Fukumoto S, Ishimura E, Miki T, Tabata T, Nishizawa Y 2004 Lower risk for cardiovascular mortality in oral 1alpha-hydroxy vitamin D3 users in a haemodialysis population. Nephrol Dial Transplant 19:179-184.
17. USRDS 2003 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. USRDS, Bethesda, MD, USA.
18. Foley RN, Parfrey PS, Sarnak MJ 1998 Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 32(Suppl 3):S112-S119.
19. Cheung AK, Sarnak MJ, Yan G, Dwyer JT, Heyka RJ, Rocco MV, Teehan BP, Levey AS 2000 Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients. Kidney Int 58:353-362.
20. Gonzalez EA, Sachdeva A, Oliver DA, Martin KJ 2004 Vitamin D insufficiency and deficiency in chronic kidney disease. A single center observational study. Am J Nephrol 24:503-510.
21. Levin A 2006 Kidneys, hearts, hormones and immunomodulators: Integrated understandings. Blood Purif 24:46-50.
22. Inoue T, Kawashima H 1988 1,25-Dihydroxyvitamin D3 stimulates 45Ca2+-uptake by cultured vascular smooth muscle cells derived from rat aorta. Biochem Biophys Res Commun 152:1388-1394.
23. O'Connell TD, Simpson RU 1996 Immunochemical identification of the 1,25-dihydroxyvitamin D3 receptor protein in human heart. Cell Biol Int 20:621-624.
24. Zittermann A, Schleithoff SS, Tenderich G, Berthold HK, Korfer R, Stehle P 2003 Low vitamin D status: A contributing factor in the pathogenesis of congestive heart failure? J Am Coll Cardiol 41:105-112.
25. Lind L, Hanni A, Lithell H, Hvarfner A, Sorensen OH, Ljunghall S 1995 Vitamin D is related to blood pressure and other cardiovascular risk factors in middle-aged men. Am J Hypertens 8:894-901.
26. Timms PM, Mannan N, Hitman GA, Noonan K, Mills PG, Syndercombe-Court D, Aganna E, Price CP, Boucher BJ 2002 Circulating MMP9, vitamin D and variation in the TIMP-1 response with VDR genotype: Mechanisms for inflammatory damage in chronic disorders? QJM 95:787-796.
27. Pfeifer M, Begerow B, Minne HW, Nachtigall D, Hansen C 2001 Effects of a short-term vitamin D(3) and calcium supplementation on blood pressure and parathyroid hormone levels in elderly women. J Clin Endocrinol Metab 86:1633-1637.
28. McGonigle RJ, Fowler MB, Timmis AB, Weston MJ, Parsons V 1984 Uremic cardiomyopathy: Potential role of vitamin D and parathyroid hormone. Nephron 36:94-100.
29. Park CW, Oh YS, Shin YS, Kim CM, Kim YS, Kim SY, Choi EJ, Chang YS, Bang BK 1999 Intravenous calcitriol regresses myocardial hypertrophy in hemodialysis patients with secondary hyperparathyroidism. Am J Kidney Dis 33:73-81.
30. Wolisi GO, Moe SM 2005 The role of vitamin D in vascular calcification in chronic kidney disease. Semin Dial 18:307-314.
31. Moe SM, Zekonis M, Harezlak J, Ambrosius WT, Gassensmith CM, Murphy CL, Russell RR, Batiuk TD 2001 A placebo-controlled trial to evaluate immunomodulatory effects of paricalcitol. Am J Kidney Dis 38:792-802.
32. Levin A, Li YC 2005 Vitamin D and its analogues: Do they protect against cardiovascular disease in patients with kidney disease? Kidney Int 68:1973-1981.